Short Interest in Orion Oyj (OTCMKTS:ORINY) Rises By 200.0%

Orion Oyj (OTCMKTS:ORINY - Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 600 shares, a growth of 200.0% from the May 15th total of 200 shares. Based on an average trading volume of 400 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.0% of the shares of the stock are sold short.

Orion Oyj Price Performance

ORINY traded up $0.73 on Thursday, hitting $36.45. 236 shares of the company's stock were exchanged, compared to its average volume of 2,135. Orion Oyj has a fifty-two week low of $21.10 and a fifty-two week high of $36.45. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $31.13 and a 200-day moving average price of $27.77. The stock has a market cap of $10.29 billion, a price-to-earnings ratio of 28.93 and a beta of 0.07.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The company reported $0.23 earnings per share (EPS) for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The company had revenue of $373.03 million for the quarter. As a group, equities analysts anticipate that Orion Oyj will post 1.18 earnings per share for the current year.

Orion Oyj Increases Dividend

The firm also recently announced a dividend, which was paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th were paid a dividend of $0.4478 per share. The ex-dividend date of this dividend was Monday, April 7th. This is a boost from Orion Oyj's previous dividend of $0.24. Orion Oyj's payout ratio is 24.43%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.